Our Mission
Fully dedicated to saving lives, curing life threatening diseases, and improving quality of life for millions of people suffering from skin disorders.
Who we are
BirchBioMed is a clinical-stage biopharmaceutical company headquartered in Canada. We are dedicated to the development of innovative treatments for organ fibrosis, scarring, related skin disorders, and specific subsets of autoimmune disorders, including Type 1 Diabetes and Alopecia Areata.
We hold exclusive, worldwide pharmaceutical licenses from the University of British Columbia (UBC) for two groundbreaking technologies: FS1 (kynurenine) and FS2 (kynurenic acid), along with AI-001, which combines KynA with APCs therapy.
Our preliminary research and early-to-mid-stage clinical trials have demonstrated that FS2 has the potential to be a revolutionary treatment for multiple life-threatening diseases and severe debilitating conditions.
Our Vision and Mission
Our mission is to position FS2, a natural and safe compound produced by the human body, as the first curative treatment for millions suffering from organ fibrosis—a condition currently fatal for nearly half of those diagnosed. Additionally, we are developing AI-001, aimed at radically improving the lives of patients with specific autoimmune disorders, initially focusing on Type 1 Diabetes and Alopecia Areata.
Beyond its potential to cure life-threatening diseases, FS2 has also demonstrated exceptional results as a topical cream in treating scars from burns and in patients with mature keloids or hypertrophic scars. Pending regulatory approvals, FS2 cream will be marketed either as an over-the-counter (OTC) or cosmetic product. Our OTC & Cosmetics Products Platform will be developed in partnership with leading companies in these sectors.